Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.59 |
| ▸ | PDE4A | P27815 | 3/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728699 | 0.87 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL728573 | 0.86 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL728515 | 0.84 | PDE4B (0.68) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL730996 | 0.84 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12081815 | 0.79 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12081752 | 0.78 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12081829 | 0.76 | PDE4B (0.55) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3675103 | 0.74 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL730520 | 0.73 | PDE4B (0.68) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4361797 | 0.71 | PDE4B (0.74) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078887-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130178498-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130116279-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8258154-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2467376-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Kalypsys, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8138205-B2 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | KALYPSYS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8080563-B2 | Bicyclic heteroaryl inhibitors of PDE4 | Kalypsys (US) | 2011-12-20 | — | — | US | disclosed |
| WO-2011093924-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100022586-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2037924-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven P. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080027099-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008006050-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178498-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4C 3/4885 |
| US-20100022586-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4C 3/4885 |
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4C 3/4885 |
| US-20080027099-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4C 3/4885 |
| US-20130116279-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4C 3/4885 |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.